Evolus Strategic Advantage and Growth

LOVEVOLUS PROJECTING $700M TOTAL NET REVENUE IN 2028 A 28% CAGR The company: Continues to expect to achieve positive non- GAAP operating income on a consolidated basis in 2025 and remains fully funded to expected profitability* Projects its total net revenue can reach $700 million by 2028, a compound annual growth rate of 28%, based on the combination of its existing aesthetic neurotoxin business and anticipated launch of the Evolysse TM HA dermal filler product line beginning in 2025 NET REVENUE $202M** $148.6M $99.7M Please refer to the "Use of Non-GAAP Financial Measures" on slide 3 Based on Preliminary Unaudited 2023 Results announced on January 16, 2024 De $700M Aspiration 2021 2022 2023 2028 28

View entire presentation